Jasper Therapeutics, Inc. (JSPR): Form 8-K filed 2026-07-17
- Accepted by EDGAR
- 2026-07-16 21:50 ET
- Event date
- 2026-07-16
- Accession no.
- 0001213900-26-078887
- Original filing
- SEC EDGAR filing index
Items reported
- Item 1.01: Entry into a Material Definitive Agreement
The company signed a material agreement outside the ordinary course of business, or materially amended one. Typical examples are credit agreements, merger agreements, large supply or licensing contracts and financing arrangements. - Item 2.01: Completion of Acquisition or Disposition of Assets
The company completed the acquisition or disposition of a significant amount of assets, including a business. The report covers the date, the assets, the counterparty and the consideration. - Item 3.02: Unregistered Sales of Equity Securities
The company sold equity securities in a transaction not registered under the Securities Act, such as a private placement, above a size threshold. - Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
A director or a named officer (such as the CEO or CFO) left or was appointed, or certain executive compensation arrangements were adopted or changed. - Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
The company amended its articles of incorporation or bylaws without a shareholder vote that was previously disclosed, or changed its fiscal year. - Item 7.01: Regulation FD Disclosure
The company is making information public under Regulation FD, which requires broad public disclosure of material information shared with certain market participants. Investor presentations and press releases are common. Like Item 2.02, this information is generally "furnished" rather than "filed". - Item 9.01: Financial Statements and Exhibits
Lists the financial statements, pro forma information and exhibits filed with the report. It almost always accompanies another Item and is rarely news on its own.
Documents
| Type | Description | Document |
|---|---|---|
| 8-K | CURRENT REPORT | ea0298229-8k_jasper.htm |
| EX-2.1 | AGREEMENT AND PLAN OF MERGER, DATED JULY 16, 2026, BY AND AMONG JASPER THERAPEUT | ea029822901ex2-1.htm |
| EX-3.1 | JASPER THERAPEUTICS, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND | ea029822901ex3-1.htm |
| EX-10.1 | FORM OF SECURITIES PURCHASE AGREEMENT, DATED AS OF JULY 16, 2026, BY AND AMONG J | ea029822901ex10-1.htm |
| EX-10.2 | FORM OF REGISTRATION RIGHTS AGREEMENT, BY AND AMONG JASPER THERAPEUTICS, INC. AN | ea029822901ex10-2.htm |
| EX-99.1 | JASPER THERAPEUTICS, INC. CORPORATE PRESENTATION, DATED JULY 16, 2026 | ea029822901ex99-1.htm |
This page lists what the filing reports; it does not summarize or interpret it. Read the original documents on SEC EDGAR. How to read an 8-K.